According to this old news state in second quarter of 2009
that would end in JUNE.
Adventrx Pharmaceuticals Inc has entered into an agreement with a new contract manufacturer to conduct process development and scale-up activities for both ANX-530 and ANX- 514. Last week, the Company attended a pre-NDA meeting with the U.S. Food and Drug Administration to discuss its NDA submission for ANX-530. The FDA requested additional information regarding the Companys new manufacturer, and as a result, ADVENTRX Pharmaceuticals, Inc anticipates the submission of its NDA for ANX-530 will take place in the second quarter of 2009.